{"type":"trials","record":{"id":41772,"source_id":"clinicaltrials-gov","external_id":"NCT05941715","title":"Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration","brief_summary":"Study purpose: To evaluate if previously high-frequent (3-5 weekly) aflibercept treated neovascular age-related macular degeneration (nAMD) can be extended in their treatment interval when switched to faricimab. Primary objective: To assess the efficacy of faricimab compared to aflibercept in terms of durability at 32 weeks by extending treatment interval in previous high-frequent aflibercept treated nAMD.","overall_status":"Completed","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Medical University of Graz","enrollment":70,"countries":["Austria"],"start_date":"2023-07-04","completion_date":"2025-02-26","last_update_date":"2025-06-06","source_url":"https://clinicaltrials.gov/study/NCT05941715","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"FAN","age_range":"50 Years","comparator":"group A: aflibercept first (part 1), switch to faricimab (part 2)","organization":"Medical University of Graz","interventions":["Aflibercept 40 MG/ML","Faricimab 120 MG/ML"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Proportion of eyes with at least one extension without retinal (intra- and subretinal) fluid within the time period bas…","Proportion of eyes with maximum extended interval without retinal (intra- and subretinal) fluid of ≥ 6, ≥ 8, ≥ 10 weeks…","Maximum extended treatment interval without retinal (intra- and subretinal) fluid — at 32 weeks and 56 weeks","Number of injections received — during 32 weeks and 1 year","Proportion of eyes remaining on a 4-weekly interval from baseline to last visit (completed interval) — at 32 weeks and…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Aflibercept 40 MG/ML","Faricimab 120 MG/ML"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05941715","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-07-04 to 2025-02-26","comparator":"group A: aflibercept first (part 1), switch to faricimab (part 2)","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.868Z","intervention":["Aflibercept 40 MG/ML","Faricimab 120 MG/ML"],"participants":70,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Proportion of eyes with at least one extension without retinal (intra- and subretinal) fluid within the time period bas…","Proportion of eyes with maximum extended interval without retinal (intra- and subretinal) fluid of ≥ 6, ≥ 8, ≥ 10 weeks…","Maximum extended treatment interval without retinal (intra- and subretinal) fluid — at 32 weeks and 56 weeks","Number of injections received — during 32 weeks and 1 year","Proportion of eyes remaining on a 4-weekly interval from baseline to last visit (completed interval) — at 32 weeks and…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41772","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}